This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Corneal Collagen Cross-linking for Progressive Keratoconus (CXL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Avedro, Inc.
ClinicalTrials.gov Identifier:
NCT00647699
First received: March 28, 2008
Last updated: December 2, 2016
Last verified: December 2016
Results First Received: May 2, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Progressive Keratoconus
Interventions: Drug: riboflavin ophthalmic solution
Device: UVA Irradiation

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Corneal Collagen Cross-linking (CXL) Treatment Group riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Control Group riboflavin ophthalmic solution without UVA irradiation

Participant Flow:   Overall Study
    Corneal Collagen Cross-linking (CXL) Treatment Group   Control Group
STARTED   73   74 
COMPLETED   65   62 
NOT COMPLETED   8   12 
Lost to Follow-up                5                4 
Withdrawal by Subject                3                8 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Corneal Collagen Cross-linking (CXL) Treatment Group riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Control Group riboflavin ophthalmic solution without UVA irradiation
Total Total of all reporting groups

Baseline Measures
   Corneal Collagen Cross-linking (CXL) Treatment Group   Control Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 73   74   147 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      7   9.6%      3   4.1%      10   6.8% 
Between 18 and 65 years      66  90.4%      71  95.9%      137  93.2% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Gender 
[Units: Participants]
Count of Participants
     
Female      19  26.0%      24  32.4%      43  29.3% 
Male      54  74.0%      50  67.6%      104  70.7% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
     
Hispanic or Latino      7   9.6%      3   4.1%      10   6.8% 
Not Hispanic or Latino      31  42.5%      36  48.6%      67  45.6% 
Unknown or Not Reported      35  47.9%      35  47.3%      70  47.6% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
     
American Indian or Alaska Native      0   0.0%      0   0.0%      0   0.0% 
Asian      0   0.0%      1   1.4%      1   0.7% 
Native Hawaiian or Other Pacific Islander      0   0.0%      0   0.0%      0   0.0% 
Black or African American      7   9.6%      7   9.5%      14   9.5% 
White      54  74.0%      61  82.4%      115  78.2% 
More than one race      0   0.0%      0   0.0%      0   0.0% 
Unknown or Not Reported      12  16.4%      5   6.8%      17  11.6% 


  Outcome Measures

1.  Primary:   Mean Change From Baseline in Maximum Keratometry (Kmax)   [ Time Frame: baseline,12 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Vineeta Belanger, VP of Clinical Affairs
Organization: Avedro, Inc.
phone: 781-768-3459
e-mail: vbelanger@avedro.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Avedro, Inc.
ClinicalTrials.gov Identifier: NCT00647699     History of Changes
Other Study ID Numbers: UVX-002
Study First Received: March 28, 2008
Results First Received: May 2, 2016
Last Updated: December 2, 2016